Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05924295 · ClinicalTrials.gov registry record · NA

Variations in Ketone Metabolism

A NA study of Ketosis, sponsored by Ohio State University.

Recruiting
Registry status
NA
Development phase
400
Enrollment target
2
Study locations

NCT05924295: Recruiting NA study of Ketosis, sponsored by Ohio State University.

NCT05924295 is a NA study of Ketosis that is actively recruiting participants, run by Ohio State University. The registered enrollment target is 400 participants, above the 31-participant average among 4 other Ketosis trials with a reported enrollment target (1190% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05924295, a NA study of Ketosis, is actively recruiting participants, sponsored by Ohio State University.

RECRUITING
Registry status
NA
Development phase
400 participants
Enrollment target
2
Study locations

Study Summary

This outcome of this study will elucidate how the phenotype of the individual modulates the KE metabolic effect. Most studies of KE have been in homogenous populations, usually young, male athletes. However, two striking experiments using identical, body weight adjusted KE doses in healthy and obese individuals found that BHB area under the curve (AUC) and removal was reduced by obesity and poor metabolic health. Similarly, ketone infusion experiments found that diabetes, obesity, and insulin resistance alter BHB metabolism. It is important to determine how obesity affects KE 'sensitivity' (i.e., breakdown and oxidation) because the increasing prevalence of obesity as a function of age. Age may be another important source of variation in ketone metabolism. The genes that control the ketone system are regulated by a cascade of transcription factors and hormones including PPARα and FGF21, which are themselves known to be affected by aging and dietary status, and the cellular protein sensor target of rapamycin (TOR). Aberrant hyperactivation of TOR with aging may reduce ketogenesis, while it was observed that a long-term ketogenic diet specifically up-regulated PPARα activity. Preliminary work revealed substantial changes across mouse lifespan in the expression of ketone-related genes in the liver such as Hmgcs2 (rate limiting for ketone production) and Bdh1 (rate limiting for BHB oxidation) between young, middle-aged, and old mice, with a nadir of gene expression in middle age before increasing again late in life. Substantial age differences were found in response to matched doses of oral KE in mice and in rats. These data may have important implications for treating people of different ages and for translating KE technologies into the Department of VA. Therefore, this project plans to study individual responses to KE ingestion across the lifespan, against the background of varying metabolic health

Primary Outcome

Difference in ketone appearance across metabolic statuses

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Ketone Supplement
  • BEHAVIORAL Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale
  • BIOLOGICAL Blood Draw
  • OTHER Urine Analysis

Study Locations (2)

California

  • The Buck Institute - Novato

Ohio

  • The Ohio State University - Columbus

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2023-06-20
Est. Completion 2027-01-01
Phase NA
Ohio State University

552 total trials

What NCT05924295 shows while recruiting

NCT05924295 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 31-participant average among 4 other Ketosis trials with a reported enrollment target (1190% higher).

The record links to 1 condition, with Ketosis appearing as the primary indexed condition, and to 4 interventions - of which Ketone Supplement is the first listed.

NCT05924295 reports a single indexed study location in California, Ohio.

Frequently Asked Questions

What is clinical trial NCT05924295 about?

NCT05924295 is a clinical study titled "Variations in Ketone Metabolism". This outcome of this study will elucidate how the phenotype of the individual modulates the KE metabolic effect. Most studies of KE have been in homogenous populations, usually young, male athletes. However, two striking experiments using identical, body weight adjusted KE doses in healthy and obese...

What is the current status of trial NCT05924295?

This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2023-06-20. Estimated completion is 2027-01-01.

What conditions does trial NCT05924295 study?

This clinical trial studies the following conditions: Ketosis.

What interventions are being tested in trial NCT05924295?

The interventions under investigation include: Ketone Supplement (DIETARY_SUPPLEMENT), Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale (BEHAVIORAL), Blood Draw (BIOLOGICAL), Urine Analysis (OTHER).

Who is sponsoring clinical trial NCT05924295?

This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05924295 being conducted?

This trial has 2 study locations across California, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ketosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01665326 · 400 participants

    Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

  • NCT02108054 · 400 participants · NA

    Behavioral and Functional Task Development, Implementation, and Testing

  • NCT02216500 · 400 participants · NA

    Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

  • NCT02250352 · 400 participants

    Core Biopsies for Establishing a Breast Tumor Tissue Repository

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05924295, the US trial registry maintained by the National Library of Medicine. NCT05924295 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.